Results 121 to 130 of about 2,581 (157)

Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis

Drugs, 2016
Lumacaftor/ivacaftor (Orkambi™) is a fixed-dose tablet containing a corrector (lumacaftor) and potentiator (ivacaftor) of the cystic fibrosis transmembrane conductance regulator (CFTR) and is the first therapy approved to treat the underlying cause of cystic fibrosis in patients (aged ≥12 years) homozygous for the most common CFTR mutation, F508del ...
openaire   +2 more sources

Ivacaftor/lumacaftor

Reactions Weekly, 2018
  +4 more sources

Ivacaftor/lumacaftor

Reactions Weekly, 2023
openaire   +2 more sources

Ivacaftor/lumacaftor

Reactions Weekly, 2022
openaire   +1 more source

Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR. A Clinical Trial

Annals of the American Thoracic Society, 2021
Scott Sagel, Umer Khan, Steven Rowe
exaly  

A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR

American Journal of Respiratory and Critical Care Medicine, 2022
Fadi Asfour, Lingyun Liu, Margaret Rosenfeld   +2 more
exaly  

Therapeutic Drug Monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis: Where Are We Now?

Pharmaceutics, 2022
Eva Choong, Laurent Decosterd, Sylvain Blanchon   +2 more
exaly  

Real-Life Safety and Effectiveness of Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis

American Journal of Respiratory and Critical Care Medicine, 2020
Dominique Hubert, Prévotat Anne, Laurence Weiss   +2 more
exaly  

Adherence to lumacaftor-ivacaftor therapy in patients with cystic fibrosis in France

Journal of Cystic Fibrosis, 2020
Stephan Garcia
exaly  

Computed Tomographic Changes in Patients with Cystic Fibrosis Treated by Combination Therapy with Lumacaftor and Ivacaftor

Journal of Clinical Medicine, 2021
Julien Mancini, Martine Reynaud-Gaubert, François Arnaud   +2 more
exaly